✦ LIBER ✦

Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model

✍ Scribed by Nobuhito Shibata; Weihua Gao; Hiroyuki Okamoto; Tomoyuki Kishida; Koji Iwasaki; Yukako Yoshikawa; Kanji Takada

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 135 KB
Volume: 91
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.10051

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Physiologically based pharmacokinetics o

Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor

✍ Akiko Kiriyama; Tomoyuki Nishiura; Hirokazu Yamaji; Kanji Takada 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

The effects of dose on the pharmacokinetic characteristics of KNI-272 were evaluated in rats after intravenous (iv) administration. The plasma kinetics of KNI-272 were dose-independent within a dose range of 1.0 to 10.0 mg/kg. However, when the dose was increased to 50.0 mg/kg, the area under the pl

Effect of parameter variability on physi

Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations

✍ Peter Varkonyi; James V. Bruckner; James M. Gallo 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB

Influence of drug transport proteins on

Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors

✍ Latoya Griffin; Pieter Annaert; Kim L.R. Brouwer 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 1 views

Comparison of a new orally potent tripep

Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-aids drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations

✍ A. Kiriyama; T. Mimoto; S. Kisanuki; Y. Kiso; K. Takada 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

## Abstract Recently, a series of KNI compounds such as KNI‐227 and KNI‐272 has been synthesized and shows potent and selective HIV‐1 protease inhibitory activity __in vitro__. In this study, we developed an HPLC assay system for KNI‐227 and KNI‐272 in rat plasma and examined the pharmacokinetic ch

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4

Novel Virtual Screening Protocol Based o

Novel Virtual Screening Protocol Based on the Combined Use of Molecular Modeling and Electron-Ion Interaction Potential Techniques to Design HIV-1 Integrase Inhibitors.

✍ Maurizio Botta; et al. et al. 📂 Article 📅 2007 🏛 John Wiley and Sons ⚖ 11 KB 👁 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.